WallStreetZenWallStreetZen

NASDAQ: TRVI
Trevi Therapeutics Inc Stock Ownership - Who owns Trevi Therapeutics?

Insider buying vs selling

Have Trevi Therapeutics Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Thomas SciasciaChief Scientific Officer2024-05-2953,368$2.55
$136.09kSell
Thomas SciasciaChief Scientific Officer2024-05-2959,354$2.19
$129.99kBuy
Lisa DelfiniChief Financial Officer2024-05-2216,043$0.51
$8.20kBuy
Lisa DelfiniChief Financial Officer2024-05-224,350$2.64
$11.48kSell
Jennifer L. GoodPresident CEO2024-05-2025,037$2.19
$54.83kBuy
Jennifer L. GoodPresident CEO2024-05-2025,037$2.86
$71.58kSell
Jennifer L. GoodPresident CEO2024-05-104,578$2.90
$13.28kSell
Jennifer L. GoodPresident CEO2024-05-104,578$2.19
$10.03kBuy
Lisa DelfiniChief Financial Officer2023-10-11785$2.02
$1.59kSell
Lisa DelfiniChief Financial Officer2023-10-112,292$0.51
$1.17kBuy

1 of 2

TRVI insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when TRVI insiders and whales buy or sell their stock.

TRVI Shareholders

What type of owners hold Trevi Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Mohamad Makhzoumi24.57%17,308,374$50.19MInsider
Anthony A. Florence Jr.24.57%17,308,374$50.19MInsider
Scott D. Sandell24.57%17,308,374$50.19MInsider
Peter W. Sonsini24.57%17,308,374$50.19MInsider
Paul Edward Walker24.57%17,308,374$50.19MInsider
Ali Behbahani24.57%17,308,374$50.19MInsider
Carmen Chang24.57%17,308,374$50.19MInsider
Forest Baskett23.23%16,359,426$47.44MInsider
Nea Management Company LLC16.14%11,370,376$32.97MInstitution
New Enterprise Associates 16 LP14.80%10,421,428$30.22MInsider

1 of 3

TRVI vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
TRVI21.99%78.01%Net BuyingNet Buying
LCTX39.24%60.76%Net BuyingNet Buying
XBIT13.12%45.17%
CHRS71.17%18.37%Net Buying
ELYM57.94%21.79%Net BuyingNet Buying

Trevi Therapeutics Stock Ownership FAQ

Who owns Trevi Therapeutics?

Trevi Therapeutics (NASDAQ: TRVI) is owned by 73.20% institutional shareholders, 259.70% Trevi Therapeutics insiders, and 0.00% retail investors. Mohamad Makhzoumi is the largest individual Trevi Therapeutics shareholder, owning 17.31M shares representing 24.57% of the company. Mohamad Makhzoumi's Trevi Therapeutics shares are currently valued at $49.16M.

If you're new to stock investing, here's how to buy Trevi Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.